Table 1.

Dose regimens for rivaroxaban in licensed indications [1, 2]

Indication	Rivaroxaban dose regimen	Dose adjustments	Duration
Prevention of stroke and systemic embolism in patients with atrial fibrillation at moderate to high stroke riska	20 mg od	15 mg od in patients with CrCl 15–49 mL/min	Ongoing provided the risk of stroke outweighs the risk of bleedingb
Prevention of venous thromboembolism in patients who have undergone major hip or knee replacement surgery	10 mg od	None	12–14 days after knee replacement 35 days after hip replacement
Treatment of deep vein thrombosis and pulmonary embolism and prevention of recurrent venous thromboembolism	15 mg bid for 3 weeks (acute treatment) 20 mg od thereafter (secondary prevention)	Nonec	Generally at least 3 months but to continue as long as the risk of recurrent VTE outweighs the risk of bleedingd
Prevention of atherothrombotic events in patients with recent acute coronary syndrome and elevated cardiac biomarkers (Europe only)e	2.5 mg bid in combination with single or dual antiplatelet therapyf	None	Based on the individual patient’s risk of ischemic events against bleeding risks

bid twice daily, CrCl creatinine clearance, od once daily

^aCHA₂DS₂-VASc score recommended to assess stroke risk [80]

^bHAS-BLED score may be useful for determining bleeding risk [80]

^cNo routine dose reduction but consider 15 mg od in patients with moderate renal impairment (CrCl 30–49 mL/min) with a high bleeding risk (Europe only) [1]

^dClinical risk scores and risk factors for bleeding can be useful for assessment [49, 50]

^eCardiac biomarkers are troponin or creatinine kinase-MB [1]

^fAcetylsalicylic acid with or without a thienopyridine (clopidogrel or ticlopidine) [1]